...Thank you very much, and thanks for having us here today, Matthew. I'm here, this is Douglas Ingram, the CEO of Sarepta. With me today as well is Ian Estepan, who is my Chief of Staff and our Head of Investor Relations as well. One thing I should say before we begin, of course, very likely you're going to ask me questions about the future. So as it relates to the risks and uncertainties of forward-looking statements, people ought to refer to our public filings to see all of the various risks that come with trying to predict the future. And if anybody wonders whether it's difficult to predict the future, I would ask people to consider how they thought about 2020 in January of this year versus now. I'll be brief in my opening comments because I'm sure there are a lot of questions. We're getting a lot done this year. We started 2020 out with an enormous task ahead of us across both of our gene therapy platform as well as our RNA platform. And then, of course, the pandemic hit, and we sent...
